ZYTIGA Receives FDA Approval For Label Update For Prolonged Survival In Metastic Castration-Resistant Prostate Cancer

ZYTIGA Receives FDA Approval For Label Update For Prolonged Survival In Metastic Castration-Resistant Prostate Cancer
shutterstock_217644481ZYTIGA received approval from the U.S. Food and Drug Administration (FDA) for a label update on March 30, 2015. The approval was based on the results of a Phase 3 clinical study showing the drug could prolong median overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC). ZYTIGA was approved in the U.S. in 2011, and since then more than 150,000 prostate cancer patients worldwide have been prescribed the therapy. The new resu
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *